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Summary 
Pancreatic cancer is a devastating disease with poor survival. At present, no effective adjuvant or palliative 
therapies are available. Unresponsiveness to chemotherapy, radiotherapy, and antihormonal treatment is one of 
the reasons that pancreatic cancer patients have an overall median survival time of 4-6 mo. This article 
summarizes clinical trials on immunotherapy of pancreatic cancer using the murine monoclonal ntibodies 
(MAbs) 17-1A and BW 494. In addition, the use of MAb treatment in combination with immune response 
modifiers is discussed. In four clinical trials, MAb 17-1A was given by iv infusion to 100 patients with 
pancreatic cancer. In 30 of these patients, antibody treatment was accompanied by),-interferon, also given 
intravenously. Complete response, partial response, and stable disease were reported in 1, 5, and 23 patients, 
respectively. Passive immunotherapy using the MAb BW 494 was carried out in 148 pancreatic cancer patients 
in two phase I and two phase II trials. In 1 out of 75 patients apartial response and in 25 out of 74 patients table 
disease were reported. However, in a controlled, randomized trial enrolling 61 patients following Whipple 
resection, comparable survival times in patients with and without MAb BW 494 treatment led to the termi- 
nation of further clinical trials with this antibody. New clinical studies using humanized MAbs in combination 
with immune response modifiers hould be initiated to further evaluate immunotherapy as atreatment option 
in pancreatic cancer. 
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Introduction 
In the age of modem diagnostic procedures and 
highly developed conservative and surgical thera- 
peutic strategies in oncology, pancreatic ancer is 
still a devastating disease with poor prognosis (1,2). 
In the past decades, the incidence of cancer of the 
pancreas has apparently been increasing, and it is 
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now the fourth leading cause of cancer death in 
Westem industrialized countries (1, 2). The therapeu- 
tic possibilities and perspectives in this malignancy 
have not changed fundamentally over the past few 
years. Although chemotherapy, radiotherapy, and 
antihormonal therapy have improved the prognosis 
of a variety of human malignancies, cancer of the 
pancreas seems not to respond to any of these treat- 
ment strategies (3-11). Only early detection of can- 
cer of the pancreas followed by resection of the 
pancreatic tumor offers the possibility to improve 
survival or cure patients with pancreatic ancer 
(2,12). However, the curative resectability rate in 
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pancreatic cancer is low and does not exceed 15-35% 
(2,12). This is because the late and unspecific symp- 
toms that lead to the diagnosis of the malignancy in
most patients occur when the tumor has already 
spread into lymph nodes or distant metastases are 
present (2,12). Therefore, at present, he overall 5-yr 
survival rate in pancreatic cancer is <1%, and only 
15--20% of the patients with curative tumor esection 
live longer than 5 yr (2). 
The reasons for the aggressiveness and the extremely 
malignant potential of pancreatic ancer are not 
known. It has been reported that pancreatic cancer 
cells overexpress the epidermal growth factor (EGF) 
receptor and its ligands EGF and transforming 
growth factor alpha (TGF-~t) (13,14). The concomi- 
tant presence of the EGF receptor with either EGF 
and/or TGF-ct or amphiregulin i  pancreatic cancer 
cells is associated with tumor aggressiveness and 
shorter patient survival periods (14,15). In addition, 
overexpression faFGF, bFGF, TGF-13s, TGF-13 recep- 
tors, c-erbB-2, c-erbB-3, c-met, HGF, as well as 
K-ras and p53 mutations are also commonly found in 
pancreatic cancer (16-25). These findings indicate 
that alterations in the expression of growth factors, 
growth factor receptors, and K-ras and p53 muta- 
tions may provide an important pathophysiological 
mechanism in pancreatic cancer and seem to give pan- 
creatic ancer cells a fundamental growth advantage. 
The dilemma for clinicians dealing with patients 
with pancreatic cancer is the lack of any effective 
palliative or curative treatment possibilities. There- 
fore, new and unconventional treatment s rategies 
must be developed, and their effectiveness has to be 
investigated in clinical trials. 
The present article deals with the results of clini- 
cal trials using the monoclonal ntibodies (MAbs) 
17-1A (MAb 17-1A), BW 494 (MAb BW 494), and 
immune response modifiers in patients with pancre- 
atic cancer. The results of these studies have been 
published in detail elsewhere (26-36). 
Immunotherapy of Pancreatic Cancer 
with the MAb 17-1A 
Rationale for the Use of the MAb 17-1A 
in the Treatment of Pancreatic Cancer 
The MAb 17-1A is a murine IgG2a isotype, which 
was developed by immunizing mice with the super- 
natant ofcolorectal carcinoma cell line SW 1038 (3 7- 
39). This MAb is immunoreactive with a variety of 
gastrointestinal malignancies, and was originally 
used in clinical trials enrolling patients with colo- 
rectal, pancreatic, and gastric ancers (40). Following 
binding to a 37-kDa glycoprotein, the MAb 17-1A 
initiates an antibody-dependent c llular cytotoxicity 
(ADCC) in the presence ofmonocytes ormacroph- 
ages (41). This means that binding of the antibody to 
the cancer cells leads to the activation of immune 
cells, which will destroy antibody-labeled cells. In 
nude mice, administration f MAb 17-1A inhibited 
the growth of human tumor and caused an increase in 
activated macrophages in the tumor mass (41). 
Clinical Trials with the MAb 17-1A 
In 1984, the first clinical trials with MAb 17-1A 
were started in patients with advanced pancreatic 
cancer. In total, 43 patients were enrolled in two phase 
II studies (26,27). The patients were treated with a 
total dosage of 400-500 mg MAb 17-1A admixed 
with approx 109 autologous mononuclear cells, 
which were isolated by standard leukopheresis tech- 
nique. Partial response was reported in four patients 
(10%). Nine patients (21%) had stable disease, and in 
69% of the patients, tumor progression was observed. 
No severe side effects of MAb 17-1A therapy were 
reported in either study. 
Thirteen of 16 patients (81%) analyzed for the 
development of human antimouse antibodies showed 
a significant human antimouse antibody (HAMA) 
response (27). The formation of anti-idiotypic 
human antimouse antibodies may lead to the pro- 
duction of human antibodies that bind again to the 
cancer cells, and may cause direct or indirect tumor 
cell destruction. 
Combination of MAb 17-1A Treatment 
with Immune Response Modifiers 
Clinical Trials with the MAb 17-1A 
in Combination with Gamma-Interferon 
(~-Interferon) 
The promising findings of these two phase II trials 
with MAb 17-1A in pancreatic cancer patients stimu- 
lated the initiation of further clinical studies. To 
enhance the efficacy of MAb 17-1A treatment, 
Tempero et al. started aphase II trial in which MAb 
17-1 A, peripheral mononuclear cells, and 7-inter- 
feron were administered simultaneously (28). y-Inter- 
feron is a potent activator of macrophages and 
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monocytes. These act as effecter cells in the ADCC 
reaction initiated by the binding of the MAb 17-1A 
to the cancer cells. In addition, ,/-interferon i creases 
the number of Fc receptors on macrophages and 
monocytes, and thereby may lead to an enhanced 
lyric rate of the tumor cells. Out of 30 patients 
treated in this manner, 25 were evaluable for 
response analysis. There was one patient with com- 
plete response (4 mo), and nine patients (36%) expe- 
rienced stable disease (duration between 4 and 48 
mo). Tumor progression was observed in 15 patients 
(60%). MAb 17-1A treatment incombination with 
y-interferon was tolerated well in all patients except 
one. This patient experienced ananaphylactic reac- 
tion owing to pre-existing human antimouse anti- 
bodies. In the other patients, no side effects of the 
treatment occurred. 
Combination of the MAb 17-1A 
with lnterleukin-2 
Combination ofMAb 17-1A with interleukin-2 in
in vitro experiments did not enhance the lytic activity 
ofMAb 17-1A treatment alone (29). Interleukin-2 is 
an inducer oflymphokine-activated killer cells, which 
are potent cytolytic ells capable oflysing natural killer 
cell-resistant tumor cells. However, the combination 
ofinterleukin-2 and MAb 17-1A failed to augment the 
lytic activity in six human pancreatic cancer cell lines. 
Therefore, no clinical studies have been started to 
analyze the combination of MAb 17-1A and inter- 
leukin-2 in patients with pancreatic cancer. 
Long-Term Treatment 
of Advanced Pancreatic Cancer 
with the MAb 17-1A 
The first clinical studies with the IgG2a murine 
MAb 17-1A employed single infusions of the MAbs 
or treatment schedules of <10 d. These treatment 
schedules were used because murine MAb 17-1A 
treatment induces human antimouse antibodies, 
which might cause hypersensitivity reactions. How- 
ever, it is not known if repeated osing schedules 
may enhance the efficacy of unconjugated MAb 
17-1A therapy in patients with pancreatic cancer. In 
1993, Weiner and coworkers published a phase II 
multicenter evaluation of prolonged MAb 17-1A 
treatment in 28 patients with unresectable pancreatic 
cancer (30). Sixteen patients received a total dosage 
of 12 g MAb 17-1A. The antibodies were adminis- 
tered in single dosages of 500 mg three times weekly 
for 8 wk. Five patients showed hypersensitivity reac- 
tions within 3 wk of the beginning of antibody treat- 
ment. Six additional patients were withdrawn from 
the study because of rapid tumor progression a d one 
was withdrawn because of violation of the study pro- 
tocol. Response evaluation was possible in 22 patients. 
One patient had partial response for more than 3 yr, 
5 patients had brief periods of stable disease, and 
16 patients (73%) had progressive tumor disease. The 
mean survival of all patients was 11.7 wk, and the 
mean progression free survival was 7 wk. Human 
antimouse antibodies were not identified in any 
patient following MAb 17-1A therapy. This phenom- 
enon may have been owing to complexing ofllAMA 
with circulating MAb 17-1 A rather than to the lack 
of HAMA production. The authors concluded from 
their results that long-term MAb 17-1A therapy in 
patients with advanced pancreatic cancer was well 
tolerated, but was not effective in prolonging survival. 
Immunotherapy of Pancreatic Cancer 
with the MAb BW 494 
Rationale for the Use of the MAb BW 494 
in the Treatment of Pancreatic Cancer 
The MAb BW 494 was developed and character- 
ized by Bosslet and coworkers in 1986 (42). It is a 
routine immunoglobulin (IgG1 isotype) that recog- 
nizes a membrane and cytoplasmic 200-kDa carbohy- 
drate antigen that is expressed in pancreatic cancer 
cells. It was derived from Balb/c mice that were immu- 
nized with the DE-TA colon carcinoma cell line (42). 
The first clinical trials with the MAb BW 494 
against pancreatic carcinoma were based on the fol- 
lowing characteristics: 
1. The antibody shows strong binding capacity to 
well and moderately differentiated human pancre- 
atic cancer cells in vitro and in vivo. Immunohis- 
tochemical nalysis revealed a binding sensitivity 
to more than 90% of pancreatic adenocarcino- 
mas (42-44); 
2. The antibody mediates ADCC with human 
mononuclear cells against 51CR_labeled pancre- 
atic cancer target cells (42); 
3. In vitro, the antibody inhibits pecific functions 
of pancreatic cancer cells, such as endocytosis, 
superoxide anion generation, and the release of 
lysosomal enzymes (45,46); and 
International Journal of Pancreatology Volume 21, 1997 
46 Friess, Gassmann, and Bftchler 
Table 1 
Clinical Trials with the MAb BW 494 in Patients with Pancreatic Cancer a 
Phase I (high dose) 
Phase I (pilot study) 
Phase II (uncontrolled) 







Ulm, Giessen, Hamburg 
Ulm, Giessen, Nijmegen 
Ulm, Nfimberg, Giessen, 
Diisseldorf, Nijmegen 
aparticipating centers: Department of Surgery, University of Ulm, Germany; 
Department of Surgery, University of Giessen, Germany; Department of Surgery, 
Klinikum Ntimberg, Germany; Department of Internal Medicine, University Hospital, 
Hamburg, Germany; Department of Internal Medicine, University of Hannover, Ger- 
many; Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine 
University D~sseldorf, Germany; Department of Internal Medicine, Division of Oncol- 
ogy, University of Nijmegen, The Netherlands. 
4. Single injection of 131 I-labeled antibody leads to 
growth suppression ofhuman pancreatic tumors 
transplanted into nude mice (47). 
Clinical Trials with the MAb BW494 
From 1985-1989, four clinical trials using the 
MAb BW 494 in 148 patients with pancreatic cancer 
were carried out (Table 1) (31-36). There were two 
phase I studies (1985-1988), one uncontrolled phase 
II study in patients with unresectable pancreatic can- 
cer (1987-1988) and one controlled, randomized 
phase II trial in patients with resectable tumors 
(Whipple resection) and no distant metastases (1987- 
1989). All four studies were multicentric and carried 
out at the Universities of Ulm, Giessen, Ntirnberg, 
Hamburg, Hannover and D~isseldorf, Germany, as 
well as Nijmegen in the Netherlands. 
MAb BW 494: Phase I Study (High Dose) 
Thirteen patients with distant metastases (M1, 
according to UICC, 1987 [48]) were included in this 
trial to determine the pharmacokinetics and dose- 
related side effects of iv MAb BW 494 application 
(32). In every two patients, a single iv infusion of 
100,200, 400, 600, 800, and 1000 mg MAb BW 494 
was applied (up to 250 mg/h). Following the end of 
the MAb infusion, a total of 16 blood samples were 
taken within 10 d, and the concentration of the 
murine IgG1 was measured. The calculated initial 
half-life of the MAb BW 494 was 12 min, and the 
terminal half-life was 47.8 h, respectively (31, 32, 34). 
Antibody dosages between 100 and 400 mg were 
well tolerated without any side effects. In starting 
higher dosages (600-1000 mg), six of eight patients 
showed side effects, such as diarrhea, vomiting, and 
abdominal discomfort (32). All side effects could be 
controlled without further complications by stopping 
the infusion and symptomatic drug treatment. 
MAb BW 494: Phase I Study (Pilot Study) 
A total of 39 patients with advanced pancreatic 
cancer (T3 or N1 or M1, according to UICC, 1987 
[48]) were included in this trial (31,32,34,35). Fur- 
ther inclusion criteria were a Kamofsky performance 
status above 30% and a predicted survival period 
longer than 3 mo. The study design also included 
laparotomy and histological proof of pancreatic 
adenocarcinoma as well as the immunohistochemi- 
cal binding analysis of MAb BW 494 in tumor 
samples. Once written informed consent was obtained 
from the patients, immunotherapy was usually started 
between the second and third postoperative w ek. In 
keeping with the design of a phase I study, three dif- 
ferent application protocols were used (Table 2). The 
first patients were treated on five successive days, 
beginning with an initial dosage of 20 mg MAb BW 
494 and increasing by 20 mg daily up to a total dos- 
age of 300 mg. The second group of patients received 
an initial dosage of 50 mg MAb BW 494, followed by 
constant dosages of 30 mg in 3-d intervals up to a 
total dosage of 150-230 mg over a total treatment 
period of 3 wk. Owing to anaphylactic side effects in 
this protocol, the mode of application was shortened 
in all further trials to a 10-d treatment protocol. The 
patients were treated with an initial dosage of 100 mg 
MAb BW 494 and subsequent i fusions of a constant 
dosage of 30 mg in the following 9 d. The antibody 
was always diluted in 100 mL of 0.9% sodium chlo- 
ride solution and administered via a peripheral vein 
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of the MAb BW 494 in Patients with Advanced Pancreatic Cancer 
47 
Duration of MAb 
application Total dosage Single MAb infusions 
1 wk 300 mg 
3 wk 230 mg 




over a time period of 30-60 min. During the antibody 
infusions, the patients were carefully monitored for 
general and cardiovascular status to control possible 
allergic reactions. The patients were followed up every 
4 wk in the outpatient clinic. They were checked for 
general clinical status, Karnofsky performance status, 
tumor progression via ultrasonography and/or con- 
trast-enhanced computed axial tomography scan, and 
for the serum tumor markers CEA and CA 19-9. 
RESULTS 
Immunohistochemical an ysis was carried out on 
a total of 14 tumor specimens. All well- and moder- 
ately differentiated tumors exhibited medium to 
intense immunostaining. However, only 50% of the 
undifferentiated pancreatic arcinomas howed 
immunoreactivity with the MAb BW 494. 
There were no side effects to immunotherapy in 
the majority of the patients. Two patients developed 
diffuse muscular aches in the lower extremities and 
in the lumbar egion 14 and 20 d after the first infu- 
sion of the MAb BW 494. These symptoms subsided 
after 48 h without specific therapy. Two patients 
experienced anaphylactic reactions during the fifth 
antibody application on d 12 and during the ninth 
antibody application on d 19 with severe back pain, 
tachycardia, nd hypotension. Those reactions were 
immediately controlled without further complications 
by ceasing the infusion of antibody and administer- 
ing analgesics, steroids, and epinephrine. Subsequent 
serum analysis indicated highly positive HAMA 
titers at the time of the infusion, which may account 
for the anaphylactic reactions. 
Similar anaphylactic reactions were observed in 
one patient, when a second antibody infusion was 
given 3 mo after the primary antibody application. 
Serum analysis also indicated high serum levels of 
HAMA in this patient. Seventeen of 18 (94%) patients 
showed HAMA production following repeated 
application of MAb BW 494. One-third of these 
HAMA were anti-idiotypic. 
One of the patients in this trial had a partial remission 
(3%), and 23% (9/39) showed stable disease for at least 
3 mo following antibody treatment. Seventy-four per- 
cent (29/39) of the patients had continuous tumor pro- 
gression. The median survival was 5 mo in all patients, 
3 mo in patients with progressive disease, and 13 mo in 
patients with partial remission or stable disease. 
MAb B W 494: Phase 11Study (Uncontrolled) 
Between 1987 and 1988, a phase II trial with pan- 
creatic ancer patients who had nonresectable tumors 
and no evidence of distant metastases was carried out 
(32). Thirty-five patients from Ulm, Giessen, and 
Nijmegen were included in this uncontrolled study. 
A total dosage of 370 mg ofMAb BW 494 was given 
intravenously within 10 d according to the third 
application regimen in the pilot study (Table 2). No 
side effects of the antibody treatment were registered. 
The median survival period for all patients was 6.5 mo. 
Forty-seven percent of the patients howed stable 
disease for at least 3 mo (WHO classification), and 
53% of the patients exhibited tumor progression. 
Partial or complete umor emission was not observed 
in any patient. 
MAb BW 494: Phase 11 Study 
(Controlled, Randomized) 
The encouraging findings of the pilot and the 
uncontrolled phase II trial with the MAb BW 494 
justified the initiation of a controlled, randomized 
study in patients with resectable pancreatic cancer 
(33). The hypothesis for this study was that if passive 
immunotherapy with the MAb BW 494 was to have 
any effect, it would be in patients with pancreatic 
cancer having the smallest possible tumor lesion. 
Sixty-five patients with suspected pancreatic can- 
cer were recruited prospectively for this study. Inclu- 
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Table 3 
Controlled, Randomized Phase II Trial in 61 Patients 
with Pancreatic Cancer and Whipple Resection a 
MAb BW 494 Control 
treatment group 
No. of patients 29 32 
Median age 59 yr 59 yr 
Min--max 29--74 yr 30-75 yr 
Sex 
Female 14 16 
Male 15 16 
aTwo weeks after surgery, the patients were randomized 
into the MAb BW 494 treatment group or into the control group 
(no MAb BW 494 treatment). 
sion criteria were tumor resectabitity, no distant 
metastases, a histologic grade 1 or 2 (according to 
UICC, 1987 [48]), a Karnofsky performance status 
>70%, and written informed consent. Two weeks 
after the Whipple resection, the patients were ran- 
domized to receive ither MAb BW 494 treatment or
no additional therapy (control group). Four patients 
were excluded because of distal common bile duct 
cancer. Sixty-one patients (Table 3) with histologi- 
cally confirmed pancreatic adenocarcinoma were 
available for final evaluation (29 patients with MAb 
BW 494 treatment; 32 patients in the control group). 
Patients in the treatment group received ivantibody 
infusions over 10 d, starting with a dosage of 100 mg 
ofMAb BW 494 and continuing with 9 infusions of 
30 mg on the following 9 d. A monthly follow-up 
consisted of physical examination, measurement of 
the serum tumor markers CEA and CA 19-9, and 
contrast-enhanced omputed axial tomography scan 
and/or ultrasonography of the upper abdomen. 
RESULTS 
Both the MAb BW 494 treatment group and the 
control group were balanced with respect to age, gen- 
der, tumor stage, and tumor grade (Tables 3 and 4). 
Sixty-two percent (16/29) of the patients in the treat- 
ment group and 72% (23/32) of the patients in the 
control group had lymph node metastases (Table 4). 
Six patients suffered from side effects of the MAb 
BW 494 treatment. Four patients had nausea nd 
vomiting (WHO, Grade 2), one had severe abdomi- 
nal pain (WHO, Grade 3), and one patient had fever 
and chilis 1 h after the final application of the MAb. 
All side effects were responsive to drug treatment, 
Table 4 
Controlled, randomized Phase II Trial-- 
TNM Classification and Tumor Grading (UICC, 1987) a
MAb BW 494 Control 
treatment group 
29 patients 32 patients 
Tx 2 3 
T1 7 4 
T2 17 21 
T3 3 4 
Nx 3 0 
NO 10 9 
N1 16 23 
M0 29 32 
G1 7 11 
G2 22 19 
G3 0 2 
Median survival 428 d 386 d 
Range 248-510 d 296-509 d
aTwenty-nine patients were randomized into the MAb BW 
494 treatment group and 32 patients into the control group 
(no MAB BW 494 treatment). 
and MAb treatment did not have to be interrupted in
any patient. The postoperative survival data were 
computed by the method of Kaplan-Meier. The 
median survival period in patients with MAb BW 
494 treatment was 428 d (range: 248-510 d), and the 
median in the control group was 386 d (range: 296- 
509 d). This difference was statistically not signifi- 
cant. Stratification of the patients with respect to age 
(older than 60 yr), sex, and staging (NO vs N 1) did not 
reveal any improvement of the median survival from 
MAb BW 494 treatment in these subgroups. The 
negative results of this study led to the termination of
further clinical trials in pancreatic cancer using the 
MAb BW 494. 
The Future Perspectives 
of MAb Treatment 
in Pancreatic Cancer 
Between 1984 and 1993, eight clinical trials were 
performed using the murine MAbs 17-1A or BW 494 
for passive immunotherapy in pancreatic cancer (26- 
36). In the case of MAb 17-1A, these studies con- 
sisted of four phase II studies. In the case ofMAb BW 
494, it consisted of a phase I trial to evaluate side 
effects of a single antibody dosage (up to 1000 mg of 
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antibody protein), apilot study (phase I) in patients 
with advanced tumor stages, an uncontrolled phase II
study in patients with unresectable pancreatic tumors, 
and a controlled, randomized phase II study in 
patients with resectable pancreatic tumors. 
Treatment with the murine MAb 17-1A and MAb 
BW 494 was well tolerated, and did not cause severe 
side effects in the majority of patients. In advanced 
tumor stages of pancreatic cancer, antibody treat- 
ment (MAb 17-1A or MAb BW 494) seemed to 
benefit one-third of the patients. However, in a con- 
trolled, randomized trial using MAb BW 494 in 
patients following Whipple resection, no improve- 
ment in the survival periods was found (33). 
The MAb 17-1A is a murine monoclonal IgG2 anti- 
body, and the MAb BW 494 is a murine monoclonal 
IgG1 antibody. They are directed against a cyto- 
plasmic and membrane antigen in pancreatic ancer 
cells (42). Binding of the MAb BW 494 to tumor cells 
initiates the activation of macrophages or of lympho- 
cytes with killer cell activity mediating direct cyto- 
toxic effects on the cancer cells (42,45,46). Similar 
effects have been shown for MAb 17-1 A and IgG3 
isotype MAbs, which have been used in uncontrolled 
clinical trials in pancreatic cancer, other gastrointesti- 
nal cancers, and malignant melanomas (49-52). 
The application of the murine MAb 17-1A and 
MAb BW 494 induced HAMAs in 13 of 16 patients 
(81%) and in 17 of 18 patients (94%), respectively. 
One third of the HAMAs were anti-idiotypic (53). 
Although these HAMAs prohibited further antibody 
applications, this idiotypic-anti-idiotypic antibody 
response suggests a self-vaccination against he 
tumor in which the anti-idiotypic antibodies bear the 
intemal image of the tumor-associated antigen (54- 
56). Antibodies against this tumor epitope produced 
by patients after MAb therapy are tumor-specific 
human antibodies that may induce further tumor 
destruction (56-58). 
The reasons for the failure ofMAb BW 494 treat- 
ment in patients with resectable pancreatic cancer 
(Whipple resection) are not readily evident. There is 
the possibility that he dosage used in this study was 
too low to saturate the target epitopes adequately 
(59). The total MAb BW 494 dosage of 370 mg in this 
randomized trial was chosen mainly for safety rea- 
sons. In other clinical trials using MAbs in the treat- 
ment of gastrointestinal tumors, the dosages used 
were higher than the total dosage of 370 mg used in 
both the uncontrolled and controlled, randomized 
phase II trials. With regard to the MAb BW 494, it 
has been demonstrated that after 3 d of immuno- 
therapy, insufficient binding of the MAb in several 
pancreatic cancer tumor areas was detectable d spite 
good vascularization (59). Therefore, therapeutic dos- 
ages for humans might have to be higher than those 
used in the patients following Whipple resection. 
Treatment of pancreatic cancer using MAbs is a 
challenging task for the future. New and more potent 
MAbs need to be developed. This includes the pro- 
duction of chimeric and humanized MAbs, which 
may make the application of higher dosages toler- 
able and clinically feasible (59, 60). In this sense, the 
effects induced by human antibodies might be greater 
than those elicited by murine antibodies. Further- 
more, the MAb treatment might be prolonged for 
months or years, which could improve the effective- 
ness of this treatment concept dramatically. A further 
improvement ofirnmunotherapy seems to be the use 
of MAbs in conjunction with immune response modi- 
fiers, such as interleukin-2, colony-stimulating fac- 
tors, or cytotoxic substances coupled to antibodies 
(61-64). The combination of MAb BW 494 with 
granulocyte-macrophage colony-stimulating factor 
(GM-CSF) has been shown to enhance the in vitro 
ADCC reaction threefold compared toMAb treatment 
alone (65). Therefore, further clinical studies are 
necessary toinvestigate he efficiency of new MAbs 
and MAb treatment in combination with immuno- 
modulators inpatients with pancreatic cancer. 
A study in patients undergoing curative surgery 
for Dukes' C stages ofcolorectal cancer eported in 
1994 that adjuvant treatment with the MAb 17-1A 
significantly reduced the overall death rate by 30% 
and the recurrence rate by 27% (66). These encour- 
aging data should stimulate further clinical trials of 
immunotherapy in pancreatic cancer as well. 
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